Erasca (ERAS) Operating Expenses (2020 - 2026)
Erasca's (ERAS) quarterly Operating Expenses came in at $187.9 million in Q1 2026, up 427.4% YoY from $35.6 million in Q1 2025, and up 476.34% on a QoQ basis from $32.6 million in Q4 2025.
Erasca (ERAS) Operating Expenses (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Operating Expenses data on file, last reported at $187.9 million in Q1 2026.
- Quarterly Operating Expenses rose 427.4% year-over-year to $187.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293.2 million (up 66.24% YoY) and the FY2025 annual result came in at $140.9 million, down 21.54% from the prior year.
- Operating Expenses advanced to $187.9 million in Q1 2026, from $32.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $187.9 million in Q1 2026 to a low of $32.6 million in Q4 2025.
- A 5-year average of $52.8 million and a median of $36.5 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses tumbled 75.47% — and 2026, when it surged 427.4%.
- Tracing ERAS's Operating Expenses over 5 years: stood at $138.1 million in 2022, then plunged by 75.47% to $33.9 million in 2023, then climbed by 5.43% to $35.7 million in 2024, then declined by 8.7% to $32.6 million in 2025, then soared by 476.34% to $187.9 million in 2026.
- The last three Operating Expenses figures came in at $187.9 million (Q1 2026), $32.6 million (Q4 2025), and $34.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 47.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.62 Mn |
| Mar 31, 2026 | 187.91 Mn |
| Dec 31, 2025 | 32.60 Mn |
| Sep 30, 2025 | 34.55 Mn |
| Jun 30, 2025 | 38.13 Mn |
| Mar 31, 2025 | 35.63 Mn |
| Dec 31, 2024 | 35.71 Mn |
| Sep 30, 2024 | 37.24 Mn |
| Jun 30, 2024 | 67.78 Mn |
| Mar 31, 2024 | 38.85 Mn |
| Dec 31, 2023 | 33.87 Mn |
| Sep 30, 2023 | 34.66 Mn |
| Jun 30, 2023 | 35.97 Mn |
| Mar 31, 2023 | 37.03 Mn |
| Dec 31, 2022 | 138.08 Mn |
| Sep 30, 2022 | 36.96 Mn |
| Jun 30, 2022 | 35.91 Mn |
| Mar 31, 2022 | 36.51 Mn |
| Dec 31, 2021 | 31.05 Mn |
| Sep 30, 2021 | 46.04 Mn |